Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 344.33 Thousand CHF | -7.72% |
| 2022 | 373.13 Thousand CHF | -22.59% |
| 2021 | 482.01 Thousand CHF | -15.05% |
| 2020 | 567.39 Thousand CHF | 3.12% |
| 2019 | 550.24 Thousand CHF | 0.0% |
| 2018 | - CHF | 0.0% |
| 2017 | - CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| 2012 | - CHF | 0.0% |
| 2011 | - CHF | 0.0% |
| 2010 | - CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 0.0% |
| 2007 | - CHF | -100.0% |
| 2006 | 126.57 Thousand CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 32.18 Thousand CHF | -8.53% |
| 2024 Q1 | 35.18 Thousand CHF | -89.78% |
| 2023 Q3 | 323.31 Thousand CHF | 39.05% |
| 2023 Q4 | 344.33 Thousand CHF | 6.5% |
| 2023 FY | 344.33 Thousand CHF | -7.72% |
| 2023 Q2 | 232.51 Thousand CHF | -10.27% |
| 2023 Q1 | 259.11 Thousand CHF | -30.56% |
| 2022 FY | 373.13 Thousand CHF | -22.59% |
| 2022 Q4 | 373.13 Thousand CHF | -16.54% |
| 2022 Q3 | 447.1 Thousand CHF | 32.69% |
| 2022 Q1 | 412.87 Thousand CHF | -14.34% |
| 2022 Q2 | 336.95 Thousand CHF | -18.39% |
| 2021 Q2 | 420.16 Thousand CHF | -14.22% |
| 2021 FY | 482.01 Thousand CHF | -15.05% |
| 2021 Q1 | 489.8 Thousand CHF | -13.68% |
| 2021 Q4 | 482.01 Thousand CHF | -7.52% |
| 2021 Q3 | 521.22 Thousand CHF | 24.05% |
| 2020 FY | 567.39 Thousand CHF | 3.12% |
| 2020 Q1 | 458.65 Thousand CHF | -16.65% |
| 2020 Q3 | 268.93 Thousand CHF | -26.21% |
| 2020 Q4 | 567.39 Thousand CHF | 110.98% |
| 2020 Q2 | 364.47 Thousand CHF | -20.53% |
| 2019 Q1 | - CHF | 0.0% |
| 2019 Q2 | 395.39 Thousand CHF | 0.0% |
| 2019 Q4 | 550.24 Thousand CHF | 0.0% |
| 2019 FY | 550.24 Thousand CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 FY | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2017 FY | - CHF | 0.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2017 Q1 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 Q3 | - CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2014 Q3 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2013 Q1 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 0.0% |
| 2012 Q4 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2012 FY | - CHF | 0.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 FY | - CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2010 Q2 | - CHF | 0.0% |
| 2010 Q4 | - CHF | 0.0% |
| 2010 FY | - CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 0.0% |
| 2007 FY | - CHF | -100.0% |
| 2006 FY | 126.57 Thousand CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BB Biotech AG | 304.9 Million CHF | 99.887% |
| Basilea Pharmaceutica AG | 128.6 Million CHF | 99.732% |
| Evolva Holding SA | - CHF | -Infinity% |
| Idorsia Ltd | 1.2 Billion CHF | 99.971% |
| Kuros Biosciences AG | 5.51 Million CHF | 93.76% |
| Molecular Partners AG | 3.65 Million CHF | 90.571% |
| Relief Therapeutics Holding AG | 4.31 Million CHF | 92.013% |
| Santhera Pharmaceuticals Holding AG | 25.06 Million CHF | 98.626% |